Development of anthrax countermeasures that may be used concomitantly in a postexposure setting requires an understanding of the interaction between these products. Anthrax immune globulin intravenous (AIGIV) is a candidate immunotherapeutic that contains neutralizing antibodies against protective antigen (PA), a component of anthrax toxins. We evaluated the interaction between AIGIV and BioThrax (anthrax vaccine adsorbed) in rabbits. While pharmacokinetics of AIGIV were not altered by vaccination, the vaccine-induced immune response was abrogated in AIGIV-treated animals. Copyright © 2013, American Society for Microbiology. All Rights Reserved.
CITATION STYLE
Malkevich, N. V., Basu, S., Rudge, T. L., Clement, K. H., Chakrabarti, A. C., Aimes, R. T., … Ionin, B. (2013). Effect of anthrax immune globulin on response to BioThrax (anthrax vaccine adsorbed) in New Zealand white rabbits. Antimicrobial Agents and Chemotherapy, 57(11), 5693–5696. https://doi.org/10.1128/AAC.00460-13
Mendeley helps you to discover research relevant for your work.